Parabilis Medicines, Inc. (PBLS)
Parabilis Medicines, Inc. (CIK 0001657677, ticker PBLS, EIN 47-4505725) reported revenue of $148,000 for Q2 FY2026 (2026-04-01 to 2026-06-30) and net income of -$52.46 million (-$52,463,000) for Q2 FY2026 (2026-04-01 to 2026-06-30), as filed in its 10-Q filed 2026-08-13 (accession 0001193125-26-349168).
Figures are as filed with the SEC in XBRL, in whole US dollars unless stated, for the company's own fiscal years (fiscal year ends December 31). The company has no annual (10-K) values here; the figures are quarterly.
Data as of Oct 21, 2026 (Olympus publication) · Markdown version
- Values are as filed by the company in its 10-K and 10-Q XBRL data. When a later filing restates a value, the latest filed value is shown and the first reported value is noted.
- Quarterly operating cash flow is usually reported year to date; such values say so in their period.
Identifiers
As published in the company's EDGAR submissions record.
| Identifier | Value |
|---|---|
| CIK | 0001657677 |
| Tickers | PBLS (Nasdaq) |
| EIN | 47-4505725 |
| SIC industry code | 2834 Pharmaceutical Preparations |
| State or country of incorporation | DE |
| Fiscal year end | December 31 |
| Filer category | <br>Emerging growth company |
| Entity type | operating |
| Olympus entity ID | org_0bweh96szf2p5nvj2tzb373jxj |
- The EIN is the one the filer gave to EDGAR. The SEC does not verify it; Olympus checks only that it has nine digits and a prefix the IRS assigns.
Latest quarterly financial metrics
The latest quarterly value of each standardised metric, with the filing it was taken from.
| Metric | Value | Fiscal period | Period | Form | Filed | Accession number | XBRL concept |
|---|---|---|---|---|---|---|---|
| Revenue | $148,000 | Q2 FY2026 | 2026-04-01 to 2026-06-30 | 10-Q | 2026-08-13 | 0001193125-26-349168 | Revenues |
| Net income | -$52,463,000 | Q2 FY2026 | 2026-04-01 to 2026-06-30 | 10-Q | 2026-08-13 | 0001193125-26-349168 | NetIncomeLoss |
| Total assets | $1,175,262,000 | Q2 FY2026 | as of 2026-06-30 | 10-Q | 2026-08-13 | 0001193125-26-349168 | Assets |
| Total liabilities | $127,528,000 | Q2 FY2026 | as of 2026-06-30 | 10-Q | 2026-08-13 | 0001193125-26-349168 | Liabilities |
| Stockholders' equity | $1,047,734,000 | Q2 FY2026 | as of 2026-06-30 | 10-Q | 2026-08-13 | 0001193125-26-349168 | StockholdersEquity |
| Operating cash flow | -$52,822,000 | Q2 FY2026 | 2026-01-01 to 2026-06-30 (year to date) | 10-Q | 2026-08-13 | 0001193125-26-349168 | NetCashProvidedByUsedInOperatingActivities |
| Diluted earnings per share | -$2.32 per share | Q2 FY2026 | 2026-04-01 to 2026-06-30 | 10-Q | 2026-08-13 | 0001193125-26-349168 | EarningsPerShareDiluted |
| Shares outstanding | 121,938,652 shares | Q2 FY2026 | as of 2026-06-30 | 10-Q | 2026-08-13 | 0001193125-26-349168 | CommonStockSharesOutstanding |
- Accession numbers link to the filing's index on SEC EDGAR.
Revenue and net income history
Every quarterly revenue and net income value served for fiscal years 2017-2026, newest first, each with its filing.
| Metric | Fiscal period | Period | Value | Form | Filed | Accession number |
|---|---|---|---|---|---|---|
| Revenue | Q2 FY2026 | 2026-04-01 to 2026-06-30 | $148,000 | 10-Q | 2026-08-13 | 0001193125-26-349168 |
| Net income | Q2 FY2026 | 2026-04-01 to 2026-06-30 | -$52,463,000 | 10-Q | 2026-08-13 | 0001193125-26-349168 |
Recent 10-K and 10-Q filings
All 10-K, 10-Q and amendment filings in EDGAR, newest first.
| Form | Filed | Period of report | Accession number | Document |
|---|---|---|---|---|
| 10-Q | 2026-08-13 | 2026-06-30 | 0001193125-26-349168 | ck0001657677-20260630.htm |
Identifier registry
The company's identifiers in the Olympus identifier registry, each with how it was linked and its source.
| Scheme | Value | How linked | Source | Published |
|---|---|---|---|---|
| SEC Central Index Key (CIK) · OLY-US-SEC-CIK | 0001657677 | published by the source | data.sec.gov/submissions/CIK0001657677.json | 2026-10-21 |
| Employer Identification Number (EIN) · US-EIN | 47-4505725 | published by the source | data.sec.gov/submissions/CIK0001657677.json | 2026-10-21 |
Former names
| Name | From | To |
|---|---|---|
| FOG PHARMACEUTICALS, INC. | 2015-11-13 | 2022-12-02 |
Sources
- EDGAR submissions (nightly bulk archive) (company profile and filings) — U.S. Securities and Exchange Commission. EDGAR snapshot sha256:f7d2a4f18cb91aae, source date 2026-10-20. https://data.sec.gov/submissions/CIK0001657677.json
- EDGAR XBRL company facts (nightly bulk archive) (financial metrics) — U.S. Securities and Exchange Commission. EDGAR snapshot sha256:01e4045aa34d7224, source date 2026-10-20. https://data.sec.gov/api/xbrl/companyfacts/CIK0001657677.json
- Published by Olympus on Oct 21, 2026.
- Source data: U.S. Securities and Exchange Commission (EDGAR). Values are as filed by the registrant; Olympus does not audit or adjust them.
- Olympus is not affiliated with or endorsed by the U.S. Securities and Exchange Commission.
Get this data from the API
The same figures, with provenance on every value, from the API (free API key, reference) or from an AI agent through the Olympus MCP server.
curl -s "https://api.olympus.new-odyssey.com/v1/sec/companies/0001657677" -H "X-API-Key: $OLYMPUS_API_KEY"
curl -s "https://api.olympus.new-odyssey.com/v1/sec/companies/0001657677/financials?period=quarterly" -H "X-API-Key: $OLYMPUS_API_KEY"
curl -s "https://api.olympus.new-odyssey.com/v1/sec/companies/0001657677/filings?limit=12" -H "X-API-Key: $OLYMPUS_API_KEY"get_sec_company_financials {"cik":"1657677"}